Navigation Links
Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Date:12/17/2007

EDMONTON, Dec. 17 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX Venture Exchange: QPT) today announced that it has signed an agreement with a multinational technology development company (the "Investor") to receive $3,000,000 to develop oncology products based on its SonoLight Technology. Under the terms of the agreement, Quest Pharma Tech Inc. ("Quest" or the "Company") has already received $1,000,000; and the balance of $2,000,000 will be paid within the next twelve months. In return for this non-equity funding, the Investor who requested to remain anonymous, will receive 35 percent of all future net revenue from the commercialization of Quest's oncology products. This agreement does not preclude Quest from out-licensing the oncology applications of SonoLight Technology to a third party.

The Company's lead oncology product from the SonoLight platform, SL052, is anticipated to enter a Phase I clinical trial for photodynamic therapy treatment of prostate cancer during the second half of 2008. The Company is also evaluating the same technology for the treatment of lung cancer and peritoneal carcinomatosis.

"I can't think of a better holiday present to our shareholders than establishing an accelerated oncology development program," said Dr. Madi R. Madiyalakan, Chief Executive Officer of Quest Pharma Tech Inc. "We are optimistic about the potential of both our oncology products and our dermatology program. Additionally, we believe that our partnerships with Paramount BioSciences and KMH Co. Ltd. will help us achieve our long-term growth objectives, including share price appreciation."

About Quest PharmaTech Inc.

The Corporation is a publicly traded (TSX Venture Exchange: QPT), Alberta-based pharmaceutical company committed to build shareholder value through discovery, development, and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions based on its proprietary photodynamic and sonodynamic therapy platform. The Company's lead product, SL017, is a topical formulation that is currently undergoing a 90 patient clinical trial in Canada for hair removal applications. Quest has signed an exclusive multinational license agreement with Paramount Biosciences, a global pharmaceutical and healthcare investment firm, to develop and market SL017 for dermatology applications. In addition, Quest also has an agreement with KMH Co. Ltd, a Korean pharmaceutical company, to market SL017 in Asia for hair removal applications.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

"TSX Venture Exchange has neither approved nor disapproved of the

information contained herein."


'/>"/>
SOURCE Quest PharmaTech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
Breaking Biology Technology:
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
Breaking Biology News(10 mins):